Cotrimoxazole Safety in Myasthenia Gravis Patients
Cotrimoxazole (trimethoprim-sulfamethoxazole) is NOT listed among medications that worsen myasthenia gravis and can be safely used when clinically indicated, though caution is warranted in patients on immunosuppression.
Key Evidence from Guidelines
The 2018 ASCO guidelines on myasthenia gravis management explicitly list medications to avoid: β-blockers, IV magnesium, fluoroquinolones, aminoglycosides, and macrolides 1. Notably, cotrimoxazole is absent from this list, indicating it does not have the same neuromuscular junction-blocking properties as these contraindicated agents.
Clinical Context Supporting Safe Use
Evidence of Therapeutic Use in MG Patients
Treatment of infections in MG: A 2020 case series documented three MG patients (including two with thymomatous MG on immunosuppression) who were successfully treated with cotrimoxazole for nocardiosis, with all patients recovering completely 2. This demonstrates both safety and efficacy in this vulnerable population.
Prophylactic use in immunosuppressed patients: Recent 2026 data from inflammatory myopathy patients (a similar immunosuppressed population often on corticosteroids) showed that TMP/SMX prophylaxis significantly reduced severe infections (HR 0.178; 95% CI 0.056-0.57; p=0.004), particularly respiratory tract infections 3. This suggests a protective benefit without exacerbating neuromuscular weakness.
Contrast with Truly Problematic Antibiotics
Recent 2025 data on fluoroquinolones and macrolides (which ARE contraindicated) showed MG exacerbation rates of 1.5-2.4% with these agents, with some cases progressing to myasthenic crisis 4. No such data exists for cotrimoxazole, reinforcing its relative safety profile.
FDA Label Considerations
The FDA label for cotrimoxazole does not list myasthenia gravis as a contraindication or precaution 5. The primary concerns relate to:
- Folate deficiency
- Hyperkalemia (especially with high-dose therapy for PCP)
- Hematologic effects in G6PD deficiency
- Drug interactions (particularly with warfarin, phenytoin, methotrexate)
Practical Clinical Algorithm
When considering cotrimoxazole in MG patients:
Verify indication is appropriate - UTI, PCP prophylaxis, nocardiosis, or other susceptible infection
Assess MG disease severity:
- Stable, well-controlled MG → Proceed with standard dosing
- Active/unstable MG → Use with neurology consultation, but not contraindicated
Monitor for non-MG adverse effects:
- Check baseline CBC, creatinine, potassium (especially if on high-dose therapy)
- Monitor for rash, cytopenias, hyperkalemia
- Avoid concurrent drugs that increase hyperkalemia risk (ACE inhibitors, high-dose trimethoprim)
Do NOT withhold cotrimoxazole due to MG diagnosis alone - the infection risk typically outweighs theoretical concerns
Important Caveats
Infection itself can trigger MG exacerbation: The underlying infection requiring antibiotics may worsen MG symptoms independent of the antibiotic choice 4
Immunosuppression context: Many MG patients are on corticosteroids and other immunosuppressants 6, 7, making them susceptible to opportunistic infections like PCP - cotrimoxazole prophylaxis may be beneficial in this setting 3
Alternative antibiotics: If cotrimoxazole is not indicated for the specific infection, choose based on susceptibility patterns rather than MG concerns, but actively avoid fluoroquinolones, aminoglycosides, and macrolides [1-1]